MNPR - Monopar Therapeutics Inc

53.2
-0.040   -0.075%

Share volume: 152,089
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$53.24
-0.04
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 18%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.93%
1 Month
-2.49%
3 Months
-25.50%
6 Months
-34.52%
1 Year
30.36%
2 Year
7,982.65%
Key data
Stock price
$53.20
P/E Ratio 
0.00
DAY RANGE
$50.22 - $53.51
EPS 
-$1.33
52 WEEK RANGE
$28.40 - $105.00
52 WEEK CHANGE
$30.36
MARKET CAP 
503.901 M
YIELD 
N/A
SHARES OUTSTANDING 
6.683 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.03
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$196,652
AVERAGE 30 VOLUME 
$185,012
Company detail
CEO: Chandler D. Robinson
Region: US
Website: monopartx.com
Employees: 10
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Recent news